Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in Relapsed/Refractory Multiple Myeloma
NCT00437034Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Oct 2010
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Jan 2007; status: terminated.
02
Drugs
aflibercept
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00437034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00437034.